Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
Ewer
Michael S
MS
Departments of Cardiology and Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Lippman
Scott M
SM
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000145:classification* / Q000175:diagnosis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases